Dog CD279/PDCD1/PD1 HEK293T Stable Cell Line

Introduction

The Dog CD279/PDCD1/PD1 HEK293T Stable Cell Line is a valuable tool for studying the function and activity of the canine immune checkpoint protein, PD-1. This stable cell line is derived from HEK293T cells and expresses the canine PD-1 protein, also known as CD279 or PDCD1. PD-1 is a critical regulator of immune responses and has been identified as a promising therapeutic target for various diseases, including cancer and autoimmune disorders. In this article, we will discuss the structure, activity, and potential applications of the Dog CD279/PDCD1/PD1 HEK293T Stable Cell Line.

Structure of PD-1

PD-1 is a type I transmembrane protein that belongs to the CD28/CTLA-4 family of immune checkpoint molecules. It is composed of an extracellular domain, a transmembrane domain, and a cytoplasmic tail. The extracellular domain contains an IgV-like domain and an IgC-like domain, which are involved in binding to its ligands, PD-L1 and PD-L2. The cytoplasmic tail of PD-1 contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM), which are important for its inhibitory function.

Activity of PD-1

PD-1 is primarily expressed on activated T cells, B cells, and myeloid cells. Its main function is to regulate immune responses and maintain immune homeostasis. PD-1 exerts its inhibitory effect by interacting with its ligands, PD-L1 and PD-L2, which are expressed on antigen-presenting cells and tumor cells. This interaction leads to the recruitment of the SHP-1 and SHP-2 phosphatases, which inhibit T cell receptor signaling and suppress T cell activation and proliferation. PD-1 signaling also promotes the differentiation of regulatory T cells, which further suppress immune responses. Additionally, PD-1 has been shown to play a role in maintaining self-tolerance and preventing autoimmunity.

Application in Flow Cytometry

The Dog CD279/PDCD1/PD1 HEK293T Stable Cell Line is a useful tool for studying PD-1 and its interactions with its ligands. This cell line can be used in flow cytometry experiments to analyze the expression of PD-1 on different immune cell populations. It can also be used to study the binding of PD-1 to its ligands and the downstream signaling events. Furthermore, this stable cell line can be used as a positive control in flow cytometry experiments to validate the specificity of anti-PD-1 antibodies.

Potential Therapeutic Target

PD-1 has emerged as a promising therapeutic target for various diseases, including cancer and autoimmune disorders. In cancer, PD-1 is upregulated on tumor-infiltrating T cells, leading to their exhaustion and dysfunction. This allows tumors to evade immune surveillance and continue to grow. Blocking PD-1 signaling with monoclonal antibodies has shown promising results in clinical trials, leading to the approval of PD-1 inhibitors for the treatment of several types of cancer. In autoimmune disorders, PD-1 has been implicated in the development of self-tolerance and preventing autoimmunity. Therefore, targeting PD-1 may be a potential strategy for treating autoimmune diseases.

Conclusion

In summary, the Dog CD279/PDCD1/PD1 HEK293T Stable Cell Line is a valuable tool for studying the structure, activity, and potential applications of PD-1 in canine immune responses. This stable cell line can be used in various experiments, including flow cytometry, to further our understanding of PD-1 and its role in disease. With the increasing interest in PD-1 as a therapeutic target, this stable cell line may also have potential applications in drug discovery and development.